Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · November 19, 2024

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Journal of the American Academy of Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the American Academy of Dermatology
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
J Am Acad Dermatol 2024 Oct 17;[EPub Ahead of Print], M Piliang, C Lynde, B King, P Mirmirani, R Sinclair, M Senna, S Forman, L Bordone, P De La Cueva Dobao, R Wolk, SH Zwillich, H Tran, D Wajsbrot, HM Ahmed, L Takiya

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading